{"id":36633,"date":"2024-11-25T10:03:43","date_gmt":"2024-11-25T09:03:43","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/?p=36633"},"modified":"2024-11-21T12:19:52","modified_gmt":"2024-11-21T11:19:52","slug":"neue-lang-und-besser-wirksame-antiretrovirale-hiv-prae-expositions-prophylaxe-fuer-frauen-cme","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2024\/neue-lang-und-besser-wirksame-antiretrovirale-hiv-prae-expositions-prophylaxe-fuer-frauen-cme","title":{"rendered":"Neue lang- und besser wirksame antiretrovirale HIV-Pr\u00e4-Expositions-Prophylaxe f\u00fcr Frauen [CME]"},"content":{"rendered":"<p>Frauen (Cisgender-Frauen) tragen ungef\u00e4hr zur H\u00e4lfte der weltweit 1,3\u00a0Millionen Neuinfektionen von HIV allj\u00e4hrlich bei . Die HIV-Pr\u00e4-Expositions-Prophylaxe (PrEP) mit Emtricitabin 200\u00a0mg plus Tenofovirdisoproxilfumarat 245\u00a0mg (F\/TDF) ist in Europa und den USA schon l\u00e4nger in dieser Indikation zugelassen und verhindert HIV-Neuinfektionen ,\u00a0. Etwa 6\u00a0Millionen Personen nehmen seither weltweit eine PrEP ein . Die PrEP muss t\u00e4glich [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Frauen (Cisgender-Frauen) tragen ungef\u00e4hr zur H\u00e4lfte der weltweit 1,3\u00a0Millionen Neuinfektionen von HIV allj\u00e4hrlich bei . Die HIV-Pr\u00e4-Expositions-Prophylaxe (PrEP) mit Emtricitabin 200\u00a0mg plus Tenofovirdisoproxilfumarat 245\u00a0mg (F\/TDF) ist in Europa und den USA schon l\u00e4nger in dieser Indikation zugelassen und verhindert HIV-Neuinfektionen ,\u00a0. Etwa 6\u00a0Millionen Personen nehmen seither weltweit eine PrEP ein . Die PrEP muss t\u00e4glich [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[122,123,6096,6095,4382,3827,125,6092,6094,6093,6097],"class_list":["post-36633","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-aids","tag-antiretrovirale-therapie","tag-capella-studie","tag-dreams-prep-studie","tag-echo-studie","tag-hiv","tag-hiv-infektion","tag-hiv-prae-expositions-prophylaxe","tag-lenacapavir","tag-prep","tag-purpose-1-studie"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/36633","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=36633"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/36633\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=36633"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=36633"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=36633"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}